Phase 3 N=10 Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study
Premenstrual Dysphoric Disorder
Primary: Change in Premenstrual Symptom Severity — 25.05; 27.36 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=665 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Recurrent Neuroblastoma
Primary: Event-free Survival Rate — 48.8; 61.8 percent probability — p=0.0082
Phase 3 N=199 Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — 6.3; -57.1 percent change — p=<0.0001
Phase 3 N=202 To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
Rheumatoid Arthritis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 33; 36; 68; 1 participants
Phase 3 N=562 Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 — -0.34; -0.02 percent — p=<0.001
Phase 3 N=132 Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
Major Depression Disorder
Primary: Number of Patients With Treatment-Emergent Adverse Events — 102 Participants
Phase 3 N=341 A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
Essential Hypertension
Primary: Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 289; 20 Participants
Phase 3 N=26 Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Hypoglycemia · Diabetes Mellitus
Primary: Number of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration — 14 participants
Phase 3 N=149 Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
Acute Hematogenous Osteomyelitis
Primary: Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment…
Phase 3 N=40 Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
Chronic Plantar Fasciitis
Primary: Responders Rate at Week 6 (Pain While Moving) — 25.0; 5.0 Percentage of participants — p==0.182
Phase 3 N=391 A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
Forehead Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
Phase 3 N=309 A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -19.3; -44.0; -49.1; -55.6 Percentage Change — p=<0.001
Phase 3 N=60 Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury
Pain
Primary: Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level) — 15.0; 20.0; 15.0; 15.0 minutes
Phase 3 N=132 To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Percentage of Participants With Incidence of Antidrug Antibodies (ADA) — 24.6; 18.2; 12.3; 6.1 Percentage of participants
Phase 3 N=315 Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
Asthma
Primary: Change From Baseline (Day 1 of Treatment Period/Visit 2) in Morning Peak Expiratory Flow (AM PEF) Over 12 Weeks in Intent-to-treat Population — 12.71; 14.51…